

Published in final edited form as:

Circ Cardiovasc Genet. 2013 February 1; 6(1): 37–46. doi:10.1161/CIRCGENETICS.111.962365.

Genome-Wide Association Study of Cardiac Structure and Systolic Function in African Americans: The Candidate Gene Association Resource (CARE) Study

Ervin R. Fox, MD^{1,*}, Solomon K. Musani, PhD^{1,*}, Maja Barbalic, PhD^{2,*}, Honghuang Lin, PhD³, Bing Yu, MS¹, Kofo O. Ogunyankin, MD⁴, Nicholas L. Smith, PhD⁵, Abdullah Kutlar, MD⁶, Nicole L. Glazer, MD³, Wendy S. Post, MD, MS⁷, Dina N. Paltoo, PhD, MPH⁸, Daniel L. Dries, MD, MPH⁹, Deborah N. Farlow, PhD¹⁰, Christine W. Duarte, PhD¹¹, Sharon L. Kardia, PhD¹², Kristin J. Meyers, PhD¹³, Yan V. Sun, PhD¹⁴, Donna K. Arnett, PhD¹⁵, Amit A. Patki, MS¹¹, Jin Sha, MS¹⁵, Xiangqui Cui, PhD¹¹, Tandaw E. Samdarshi, MD, MPH¹, Alan D. Penman, PhD¹, Kirsten Bibbins-Domingo, MD, PhD¹⁶, Petra Bůžková, PhD¹⁷, Emelia J. Benjamin, MD¹⁸, David A. Bluemke, MD, PhD¹⁹, Alanna C. Morrison, PhD², Gerardo Heiss, MD²⁰, J. Jeffrey Carr, MD, MSc²¹, Russell P. Tracy, PhD²², Thomas H. Mosley, PhD¹, Herman A. Taylor, MD¹, Bruce M. Psaty, MD, PhD²³, Susan R. Heckbert, MD, PhD²³, Thomas P. Cappola, MD, ScM²⁴, and Ramachandran S. Vasan, MD³

¹Dept of Medicine, University of Mississippi School of Medicine, Jackson, MS

²Human Genetics Center, University of Texas Health Science Center, School of Public Health, Houston, TX

³Dept of Medicine, Boston University School of Medicine, Boston, MA

⁴Dept of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL

⁵Dept of Epidemiology, University of Washington School of Medicine & Seattle Epidemiologic Research and Information Center, Department of Veterans Affairs Office of Research & Development, Group Health Research Institute, Group Health Cooperative, Seattle, WA

⁶Dept of Medicine, Georgia Health Sciences University, Augusta, GA

⁷Dept of Medicine, Division of Cardiology, John Hopkins School of Medicine, Baltimore, MD

⁸National Heart Lung and Blood, NIH, Health & Human Services, Bethesda, MD

Address for correspondence: Ervin Fox, MD MPH, FAHA, FACC, Professor of Medicine, Department of Medicine, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, Tel: 601-984-5630, Fax: 601-984-2631, efox@medicine.umsmed.edu.

*contributed equally as joint first authors

Conflict of Interest Disclosures: Abdullah Kutlar, MD received research grants from NIH/NIMHD-P20, Novartis, Celgene Corp (\$10,000), and Global Iron Summit (<\$10,000). Dina N. Paltoo, PhD, MPH has ownership interest in 529 College Plan and Thrift Saving Plan (> \$10,000). Sharon L. Kardia, PhD received research grants from R01 HD067264, RC4 AG039029, R01 HL101161-01-A1, R01, DK077950-03, RC1 HL100185, and P60 MD002249 (> \$10,000). Yan V. Sun, PhD received research grants from NIH HL 100245, Genetics of Hypertension Risk Factors and Sequela in African Americans (> \$10,000). Emelia J. Benjamin, MD received research grants from R01 HL09257, RC1 HD101056, R01 HL102214, R01 AG028321 (All NIH grants > \$10,000). Russell P. Tracy, PhD received research grants from Candidate Gene Association Resource Study, Exome Sequencing Project (> \$10,000). Thomas H. Mosley, PhD received research grants from ARIC, ARIC- Neurocognitive Study, Predictors of Coronary Artery Calcification in an African Americans Cohort, GWAS of Ischemic Brain Vascular Injury, ARIC PET Amyloid Imaging Study, the Intracranial Atherosclerosis Disease and Cognitive Impairment Study, Parkinson Disease and Olfactory Function in the ARIC Study, and Identify Epidemiological Risk Factors for Abdominal Aortic Aneurysm Study (All NIH grants >\$10,000). Herman A. Taylor, MD received research grants Jackson Heart Study (NIH grant >\$10,000). Bruce M. Psaty, MD, PhD received NIH grants (<\$10,000); he serves on the DSMB for a clinical trial for a device (Zoll Life Cor <\$10,000) and service on the Steering Committee for Yale Open Data Project (Medtronic <\$10,000). Susan R. Heckbert, MD, PhD received research grants from HL 087652 Whole genome association study in the Cardiovascular Health Study (NHLBI >\$10,000). Ramachandran S. Vasan, MD receives a NIH grant (>\$10,000).

- ⁹Dept of Medicine, Cardiovascular Division, Yale School of Medicine, New Haven, CT
- ¹⁰Broad Institute of Massachusetts Institute of Technology & Harvard University, Boston, MA
- ¹¹Dept of Biostatistics, University of Alabama, Birmingham, Birmingham, AL
- ¹²Dept of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI
- ¹³Dept of Ophthalmology & Visual Sciences, University of Wisconsin School of Medicine & Public Health, Madison, WI
- ¹⁴Dept of Epidemiology, Rollins School of Public Health, Emory University School of Medicine, Atlanta, GA
- ¹⁵Dept of Epidemiology, School of Public Health, University of Alabama, Birmingham, Birmingham, AL
- ¹⁶Dept of Medicine, University of California, San Francisco, San Francisco, CA
- ¹⁷Dept of Biostatistics, University of Washington, Seattle, WA
- ¹⁸Dept of Epidemiology, Boston University School of Public Health, Boston, MA
- ¹⁹Radiology & Imaging Sciences, National Institute of Health, Clinical Center, Bethesda, MD
- ²⁰Dept of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC
- ²¹Wake Forest University School of Medicine, Public Health & Translational Sciences, Salem, NC
- ²²Dept of Pathology & Laboratory Medicine, University of Vermont College of Medicine, Burlington, VT
- ²³Cardiovascular Health Research Unit, Depts of Medicine, Epidemiology, and Health Services University of Washington, Seattle, WA
- ²⁴Dept of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA

Abstract

Background—Using data from four community-based cohorts of African Americans (AA), we tested the association between genome-wide markers (SNPs) and cardiac phenotypes in the Candidate-gene Association REsource (CARE) study.

Methods and Results—Among 6,765 AA, we related age, sex, height and weight-adjusted residuals for nine cardiac phenotypes (assessed by echocardiogram or MRI) to 2.5 million SNPs genotyped using Genome-Wide Affymetrix Human SNP Array 6.0 (Affy6.0) and the remainder imputed. Within cohort genome-wide association analysis was conducted followed by meta-analysis across cohorts using inverse variance weights (genome-wide significance threshold= 4.0×10^{-07}). Supplementary pathway analysis was performed. We attempted replication in 3 smaller cohorts of African ancestry and tested look-ups in one consortium of European ancestry (EchoGEN). Across the 9 phenotypes, variants in 4 genetic loci reached genome-wide significance: rs4552931 in *UBE2V2* ($p=1.43 \times 10^{-07}$) for left ventricular mass (LVM); rs7213314 in *WIFI1* ($p=1.68 \times 10^{-07}$) for LV internal diastolic diameter (LVIDD); rs1571099 in *PPAPDC1A* ($p=2.57 \times 10^{-08}$) for interventricular septal wall thickness (IVST); and rs9530176 in *KLF5* ($p=4.02 \times 10^{-07}$) for ejection fraction (EF). Associated variants were enriched in three signaling pathways involved in cardiac remodeling. None of the 4 loci replicated in cohorts of African ancestry were confirmed in look-ups in EchoGEN.

Conclusions—In the largest GWAS of cardiac structure and function to date in AA, we identified 4 genetic loci related to LVM, IVST, LVIDD and EF that reached genome-wide

significance. Replication results suggest that these loci may represent unique to individuals of African ancestry. Additional large-scale studies are warranted for these complex phenotypes.

Keywords

echocardiography; ethnic; genome-wide association studies; Left atrium genetics; left ventricular mass genetics

Introduction

Although a number of traditional cardiovascular risk factors contribute substantially to interindividual variation in cardiac structure and systolic function, much of the observed variation in cardiac target organ damage is unexplained by established environmental risk factors, and may be attributable to genetic factors.¹ Both animal^{2–4} and human^{5–10} studies support a genetic influence on left ventricular (LV) structure and function. In a relatively recent 100K SNP genome-wide association study (GWAS) in the Framingham Heart Study, investigators confirmed modest-to-strong heritabilities (estimates 0.30–0.52) for several echocardiographic traits in white participants of European descent.¹¹ More recently, Vasan et al. conducted a GWAS using 2.5 million single nucleotide polymorphisms (SNPs) in a combined sample of 12,612 individuals of European ancestry from 5 community-based cohorts and identified 5 genetic loci associated with variation in phenotypes of cardiac structure.¹² Data on genetic influences on cardiac structure and function in African Americans are quite limited. Analyses from the Hypertension Genetic Epidemiology Network (HyperGEN), and the Genetic Epidemiology Network of Arteriopathy (GENOA) studies suggest a high heritability of LV mass (estimates ranging from 0.55–0.88), and genetic influences on LV geometric remodeling.⁸

The genome-wide association method to identify novel SNPs contributing to the underlying risk for complex diseases has been successful.¹³ African American data from the Candidate-gene Association REsource (CARE) Study allowed us to perform the first AA GWAS on cardiac phenotypes assessed by either echocardiography or magnetic resonance imaging (MRI).

Methods

CARE Consortium

Details of the CARE consortium are described elsewhere.¹⁴ Briefly, the CARE Study consists of 9 population-based cohort studies sponsored by the National Heart, Lung, and Blood Institute. Within CARE, 4 cohorts with African Americans (the Atherosclerosis Risk In Communities [ARIC], the Coronary Artery Risk Development in Young Adults [CARDIA], the Jackson Heart Study [JHS], and the Multi-Ethnic Study of Atherosclerosis [MESA]) had both echocardiography or MRI data, and DNA data available to investigate genome-wide associations (GWA). These 4 cohorts were used for the discovery phase of this investigation. Guidelines on collaboration, phenotype harmonization, covariate selection, and the analysis plan for both within-cohort GWA and prospective meta-analysis of results across studies were adopted by each study. Also each CARE cohort obtained approval from the respective institutional review boards for consent procedures, examination and surveillance components, data security measures, and DNA collection and its use for genetic research.

Echocardiographic and MRI Methods

Details on the collection of echocardiographic and MRI data by cohort are discussed in Appendix Section I. In 3 of the cohorts, participants underwent routine transthoracic

echocardiography at selected examinations (visit1 for JHS and ARIC and visit 3 for CARDIA). For MESA, participants underwent cardiac MRI at visit 1. For participants undergoing echocardiography, M- mode measurements of LV internal diastolic and systolic diameter (LVDD and LVSD), the thickness at end-diastole of the posterior wall (PWTD) and interventricular septum (IVSTD), and the diameter at end-systole of the aortic root (ARD) and the LA diameter (LAD) were obtained using the American Society of Echocardiography (ASE) guidelines. LVM was calculated by using the ASE corrected formula by Devereux:

$$0.8 [1.04\{(LVDD+IVS+PW)^3-(LVDD)^3\}]+0.6.$$

15

LV systolic dysfunction on echocardiogram was defined as the presence of reduced fractional shortening (<0.29 - which corresponds to an ejection fraction of 0.50) on M-mode or a depressed ejection fraction (<0.50) on two-dimensional echocardiography.

For MESA, LVM and LV ejection fraction were determined by cardiac MRI using 1.5-T magnets. Specifically, LVM was determined by taking the difference between the epicardial and endocardial areas for all slices, multiplying the result by the slice thickness and section gap, and multiplying that result by the specific gravity of myocardium

Genotyping Methods and Imputation

Genotyping and quality control

Genotyping of all cohorts was performed at the BROAD institute of Harvard and MIT using Affymetrix Genome-Wide Human SNP array 6.0 (Affy6.0), which interrogates simultaneously 1.8 million markers for genetic variation (906,600 SNPs and 946,000 copy number variation probes) under the CARE consortium.¹⁶ Quality control of genotyped data (SNPs) was performed using the BROAD genetic analysis platform (GAP) that consists of PLINK¹⁷ and Birdseed v1.33¹⁶ software. Quality control measures included removal of samples with genotyping success rate <95%, monomorphic SNPs, SNPs that mapped to several loci in the human genome, and SNPs with minor allele frequency (MAF) <1%. Samples with very low (< 4 standard deviation units, SD) heterozygosity suggesting poor DNA quality and samples with very high (> 4 SD) heterozygosity suggesting sample contamination were also removed. In all cohorts except for JHS, relatedness was identified by computing identical by descent (IBD) and identical by state (IBS) scores across the datasets. All pairs that shared 5% of their genome were removed, as were samples that did not cluster well when subjected to multidimensional scaling (MDS) or genome-wide “neighbor” analysis in PLINK. This was done to eliminate familial correlation. For the family-based sub cohort of the JHS, early analytical assessment by CARE investigators found little effect on inflation factor due to familial correlation. Other quality control filters included removing SNPs: for which genotype missingness can be predicted by surrounding haplotypes; with Mendelian inconsistencies and those with significant deviation from Hardy-Weinberg equilibrium. In total, 113,238 SNPs were excluded in ARIC; 69,710 in CARDIA; 40,653 in JHS; and 27,956 in MESA i.e. >99% genotyping success rate.

Genotype imputation

Genotype imputation performed in CARE has been detailed elsewhere. Briefly, in CARE, imputation was performed using the MACH <http://www.sph.umich.edu/csg/abecasis/MaCH/>) program with HapMap phase 2 (build 36 release 22) as input. Since the African-

American population is admixed with the proportion of European ancestry estimated to be ~17–19%,^{18, 19} an artificial reference panel consisting of equal proportions of the YRI and CEU HapMap phased haplotypes (using only SNPs found in both YRI and CEU panels, i.e. ~2.2M SNPs) was constructed. Hao et al. suggested that the accuracy of using the mixed panel for African-Americans is comparable to the accuracy reported when imputing a population of Nigerians using YRI as a reference panel.²⁰

Statistical Methods

Because participants within and between cohorts were unrelated, we used logistic or linear regression (implemented in PLINK genetic software) to investigate the association of SNP alleles with dichotomous or continuous echo trait, respectively assuming an additive genetic model. Fractional shortening and ejection fraction were the only 2 dichotomous cardiac traits. In these 2 traits, we compared cases to controls while adjusting for age, sex, weight, height and site (for CARDIA and MESA cohorts only) after excluding participants who had a previous myocardial infarction. For the 7 continuous traits (LVM, PWTD, IVSTD, LVIDD, LVISD, LAD, ARD), we used linear regression of log-transformed measures to obtain sex-specific residuals after adjusting for age, weight and height. The sex-specific residuals were then pooled, and within-cohort linear associations of SNP alleles with each echocardiographic continuous trait were performed. Ten principal components calculated from selected ancestry informative markers were used to account for population stratification common in African Americans due to admixture.

Genomic control correction was applied in each study prior to the meta-analysis, which ensured that the inflation factor lambda (λ) is maintained around unity.

Within-cohort genome-wide association results included parameter estimates (beta regression coefficient and their standard errors). Meta-analysis was conducted using METAL software (<http://www.sph.umich.edu/csg/abecasis/metal/>). For each SNP, METAL calculated an overall beta estimate, z-statistic and p-value from the weighted average of individual's statistic. No filtering on minor allele frequency was used.

A priori genome-wide statistical significance threshold of 4.0×10^{-07} was chosen to represent the probability for at least one SNP to have a p-value below a very stringent threshold. This strategy has been employed in GWA studies to reduce false discovery rates.^{12, 21}

Pathway analysis

We assigned the overall association significance of each genetic variant to the cardiac structure equivalent to the most significant p-value among the nine cardiac traits. We then mapped these genetic variants back to the human genome (NCBI Build 36, 2006) and RefSeq genes. A gene region was defined as between 110kb upstream and 40kb downstream of the gene's most extreme transcript boundaries, which would encompass the majority of its cis-eQTLs.²² The lowest p-value of SNPs within the gene region was assigned as the significance score for the gene. Of the 22,374 genes evaluated, 1718 reached significance scores less than 1.0×10^{-4} . These genes were then imported into Ingenuity IPA for pathway analysis (Ingenuity Systems, Redwood, CA). Fisher's exact test was used to justify the enrichment significance of each of the canonical pathways.

Replication analysis in Cohorts of African and European Ancestry and Reciprocal Look-ups of Top Loci in Cohorts of European Ancestry

Genome-wide significant SNPs discovered in the meta-analysis of the three cohorts were subjected to replication analysis in three cohorts of African ancestry (GENOA, N=651;

HyperGEN, N=1316; CHS, N=501) and one cohort of European ancestry (Echo Genetics-EchoGEN; N=12,612). We adopted a criterion for declaring significance in the replication analysis at significance level $p = 0.05/\text{number of SNPs sent for replication}$. Additionally, we performed a look-up of the top 50 CARE hits in the EchoGEN cohort. Subsequently, we tested the five published genome-wide significant SNPs from the EchoGEN cohort analysis in our CARE AA sample.

Results

The demographic and clinical characteristics of the 4 populations in the discovery meta-analysis are summarized in Table 1. The age range for most of the participants was comparable, except for CARDIA that had younger participants (<31 years old) overall. Of the 4 cohorts, only JHS had all 9 echocardiographic phenotypes, the remaining 3 cohorts measured different subsets of phenotypes. Magnetic resonance imaging was available in MESA only.

The per-cohort genomic inflation factor (λ) was consistently below 1.02 for all traits studied. The post-meta-analytic λ was also below 1.02, indicating absence of systematic inflation. The meta-analysis quantile-quantile (Q-Q) plots of observed against expected p-value distributions are shown in Appendix, Section IV, Supplementary Figure 1 (Panels A–H).

We identified 4 genome-wide significant loci associated with LV mass, IVST, LV internal diastolic diameter and LV ejection fraction < 0.50 (Table 2). Genetic effects (β) and standard errors (SE), minor and major alleles, minor allele frequency, SNP type and the nearest genes (within ~500 kbp of either site of the SNP) are also shown in Table 2. Figure 1 (Panels A–D) summarizes the primary findings from meta-analysis and displays the genome-wide $-\log_{10} p$ values for interrogated SNPs across the 22 autosomal chromosomes separately for the four cardiac traits that were significantly associated with the four loci. Figure 2 (Panel A–D) shows the forest plots associated with the top loci. Beta coefficients (for continuous traits: LV mass, IVST and LV diastolic diameter) and odds ratios (for the dichotomous trait LV ejection fraction < 0.50) from each cohort analysis and from the meta-analysis are shown. Figure 3 (Panels A–D) shows the regional plots for the four top SNPs. The nearest gene loci to the top SNPs within 500kb are also shown.

Appendix, Section IV, Supplementary Table I lists 7 additional top genetic loci (and the SNP at each locus with the lowest p value) associated with cardiac traits based on the criterion $5.0 \times 10^{-07} < p < 9.9 \times 10^{-07}$ (arbitrary threshold). In Appendix, Section IV, Supplementary Figure 2 (Panels A–G), the regional plots of the 7 additional top loci are presented.

Pathway analysis

We examined the interaction and relationship between the top GWAS loci. Accumulating evidence suggests that complex diseases and traits usually result from the incremental effects of many genetic variants.^{23–25} Pathway analysis provides a potential route to investigate the collective effects of multiple genetic variants on biological systems.^{26–28}

A total of 1718 genes were found moderately related to cardiac structure. Ingenuity IPA (Ingenuity Systems, Redwood, CA) was used to study if these genes were significantly enriched in some specific biological pathways beyond that expected from random distribution. Our analysis reveals that three canonical pathways were most significantly enriched with cardiac related genes, including the sonic hedgehog signaling pathway [6 CARE genes/33 total genes in the pathway (18.2%), $p=1.88 \times 10^{-2}$], the cardiac β -adrenergic

signaling pathway [16 CARE genes/151 total genes in the pathway (10.6%), $p=3.22\times 10^{-2}$], and the oncostatin M signaling [6 CARE genes/35 total genes in the pathway (17.1%), $p=3.88\times 10^{-2}$]. The results suggest that the disruption of these signaling pathways might be the potential mechanisms affecting cardiac structure and related echocardiographic traits, which are also implicated in previous studies. A table showing the list of the gene symbols and names from the CARE dataset identified in each of the three pathways is shown in Appendix, Section IV, Supplementary Table II.

We applied the same pathway approach to EchoGen dataset, and identified 942 cardiac-related genes with $p < 1.0\times 10^{-4}$ (see Methods). Only a small proportion of them (97 genes) were also classified as cardiac related genes from CARE dataset due to factors such as the sample size and population stratification. Interestingly, one of the most enriched pathways from CARE dataset, cardiac β -adrenergic signaling pathway, was also moderately enriched in the EchoGen dataset ($p=0.069$). (Appendix, Section IV, Supplementary Figure 3)

Independent replication of top CARE SNPs in cohorts of African and European Ancestry

Replication cohorts for the study are described in detail in Appendix Section II, Supplementary. The four top genome-wide significant SNPs in the CARE analyses were submitted for lookup in four AA cohorts the GENOA study ($n=651$), the HyperGEN study ($n=1316$), and CHS ($n=501$). Additionally top SNPs were submitted for lookup in one large cohort of EA individuals [EchoGEN ($n=12,612$)]. None of the top SNPs met the *a priori* criteria for replication in the meta-analysis of AA cohorts after correcting for multiple comparisons. None of three SNPs available in EchoGEN (rs4552931, rs7213314, and rs9530176) replicated.

Reciprocal Look-ups of Top Loci in cohorts of European Ancestry

We tested the top 50 CARE SNPs for each trait in the EchoGen consortium (exclusively European ancestry). There was a moderate association between nine of the CARE SNPs and key phenotypes of cardiac structure in EchoGen. Specifically, rs13241730 (ARD, $p=1.18\times 10^{-5}$) was associated with systolic dysfunction ($p=0.00925$); rs11187518 (EF, $p=4.44\times 10^{-6}$) with LV wall thickness ($p=3.94\times 10^{-5}$); rs7159121 (FS, $p=4.67\times 10^{-6}$) with FS ($p=0.000862$); rs1549850 (ISD, $p=1.36\times 10^{-5}$) with ARD ($p=0.00142$); rs4752424 (LVSTD, $p=1.95\times 10^{-5}$) with LVM ($p=0.00088$); rs11758777 (LAD, $p=9.29\times 10^{-6}$) with left atrial size ($p=0.00911$), rs9536417 (LVDD, $p=1.19\times 10^{-5}$) with FS ($p=0.00113$); rs6907666 (LVM, $p=1.45\times 10^{-5}$) with ARD ($p=0.000566$); and rs33432 (PWT, $p=1.94\times 10^{-5}$) with LVDD ($p=0.0106$). We tested whether the top 5 hits from EchoGEN replicated in CARE and did not find replication of any of the 5 SNPs.

Discussion

In this largest African American study assessing the influence of genetic variation on cardiac structure and function, we identified 4 genome-wide significant loci associated with LV structure (1 SNP for LV mass, 1 SNP for IVST, and 1 for LV internal diastolic dimension) and 1 significant locus associated with LV systolic dysfunction based on LV ejection fraction < 0.50 or fractional shortening < 0.29 . Findings from the replication analysis of the four genome-wide significant loci in European ancestry suggest that these SNPs may represent loci specific to African ancestry. In further analysis, we found that nine of the top 50 hits were noted to be moderately associated with cardiac structure in a large European ancestry cohort.

All of the genome wide significant loci and a number of the other top loci identified that were near (but did not reach) the threshold for genome-wide significance were near genes that can be linked to biological pathways implicated in influencing cardiac structure and function. Descriptions of these loci and nearby genes are noted in Appendix, Section V and Section VI.

In a pathway analysis we noted top loci were enriched in cardiac genes from three signaling pathways (the sonic hedgehog pathway, the cardiac β -adrenergic signaling pathway and the oncostatin M signaling pathway). Genes in the sonic hedgehog pathway have been identified in the adult heart and probably plays a role in normal cardiac homeostasis and function. This pathway is key in the embryonic development of the coronary vasculature. Several genes in the β -adrenergic signaling pathway were represented among the top hits. It is established that this pathway is important in the induction and maintenance of cardiac hypertrophy, in the redistribution of myosin isoforms, and in cardiac contractility. Further supporting our finding in the adrenergic pathway is that a similar analysis performed in the EchoGen consortium also revealed genes moderately enriched in this pathway. Finally, the oncostatin M signaling pathway was identified in the supplemental analysis. Oncostatin M is an inflammatory mediator; the signaling pathway involving oncostatin M has been found to induce stromal derived factor-1 protein secretion in human cardiac cells and play a role in repair and tissue regeneration.

Our results suggest that population stratification may complicate the discovery of genetic variants associated with cardiac structure and function, despite the evidence of shared mechanisms. It is thus necessary to investigate genetic variants specific to AA.

Strengths and Limitations

The fact that there was no replication of the top loci in populations of European ancestry suggests that the association of these loci with cardiac structure and function may be unique to African ancestry. One limitation to replication is that the African American community represents an admixed population with smaller LD blocks compared to those of European ancestry. There is significant heterogeneity among individuals within the ethnic group. Therefore, replicating findings of our study population is more challenging compared to those from cohorts of European ancestry despite the use of ancestral informative markers. Because HyperGEN and GENOA are family studies ascertained on hypertension, and therefore, enriched with genes that contribute to elevated blood pressure (assuming blood pressure is genetically determined, which remains the prevailing thought) it is not completely unexpected that our results did not replicate in these cohorts. These families might have a distinct ‘hypertension-induced’ phenotype. Another limitation of the current study is that differences in study design and data collection between cohorts may lower our statistical power to detect modest genetic effects in GWA. Using GWA, we are focused on detecting multiple variants with small effects that influence complex diseases; our statistical power in this study to detect rare variants associated to phenotypes of cardiac structure and function is limited. Additionally, we acknowledge that we are only able to identify an association between genetic loci and phenotypes of interest; we are not able to establish a cause-effect relation or to identify a mechanism leading to the association. Finally, the cohorts studied were all of African ancestry descent, limiting the generalizability of our findings to individuals of non-African ancestry.

These limitations are balanced against our ability to conduct the largest GWA on the African Americans with participants from community-based cohorts (each using standardized methods of M-mode echocardiography or MRI with quality control procedures in individual imaging laboratories) and with harmonization of imputation strategies and analytical methods into a prospective meta-analysis.

Conclusions

Our prospective meta-analysis of cardiac structure and function from over 6,765 participants in four community-based cohorts identified four loci rs4552931 in *UBE2V2* on chromosome 8 for left ventricular mass, rs7213314 in *WIP1I* on chromosome 17 for left ventricular internal diameter in diastole, rs1571099 in *PPAPDC1A* on chromosome 10 for interventricular septal wall thickness; and rs9530176 in *KLF5* on chromosome 13 for ejection fraction.

In a pathway analysis, top loci in the meta-analysis were significantly enriched with genes from the sonic hedgehog signaling pathway, the cardiac β -adrenergic signaling pathway and the oncostatin M signaling pathway.

After testing the top 50 CARE SNPs for each trait in the EchoGen consortium, we observed moderate association between nine of these SNPs with cardiac structure in EchoGen.

Implications

Identification of genetic variations that contribute to cardiac structure and function through GWA analysis may help us better understand the role genes play in development and progression of cardiac end organ damage in African Americans. This is particularly important given the current racial disparity in LV hypertrophy and dysfunction (both of which are predictors of cardiovascular morbidity and mortality). Findings in this study warrant further investigation including replication analysis in much larger samples, and identification of potential biological mechanisms explaining the association of these variants to phenotypic findings on cardiac imaging.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors wish to acknowledge the support of the National Heart, Lung, and Blood Institute and the contributions of the research institutions, study investigators, field staff and study participants in creating this resource for biomedical research. We provide below nine parent studies have contributed parent study data, ancillary study data, and DNA samples through the Broad Institute (N01-HC-65226) and their respective funding sources to create this genotype/phenotype data base for wide dissemination to the biomedical research community.

Funding Sources: *Atherosclerotic Risk in Communities (ARIC)*: University of North Carolina at Chapel Hill (N01-HC-55015), Baylor Medical College (N01-HC-55016), University of Mississippi Medical Center (N01-HC-55021), University of Minnesota (N01-HC-55019), Johns Hopkins University (N01-HC-55020), University of Texas, Houston (N01-HC-55017), University of North Carolina, Forsyth County (N01-HC-55018); *Cardiovascular Health Study (CHS)*: University of Washington (N01-HC-85079), Wake Forest University (N01-HC-85080), Johns Hopkins University (N01-HC-85081), University of Pittsburgh (N01-HC-85082), University of California, Davis (N01-HC-85083), University of California, Irvine (N01-HC-85084), New England Medical Center (N01-HC-85085), University of Vermont (N01-HC-85086), Georgetown University (N01-HC-35129), Johns Hopkins University (N01-HC-15103), University of Wisconsin (N01-HC-75150), Geisinger Clinic (N01-HC-45133), University of Washington (N01-HC-55222, U01 HL080295); *Cleveland Family Study (CFS)*: Case Western Reserve University (RO1 HL46380-01-16); *Cooperative Study of Sickle Cell Disease (CSSCD)*: University of Illinois (N01-HB-72982, N01-HB-97062), Howard University (N01-HB-72991, N01-HB-97061), University of Miami (N01-HB-72992, N01-HB-97064), Duke University (N01-HB-72993), George Washington University (N01-HB-72994), University of Tennessee (N01-HB-72995, N01-HB-97070), Yale University (N01-HB-72996, N01-HB-97072), Children's Hospital-Philadelphia (N01-HB-72997, N01-HB-97056), University of Chicago (N01-HB-72998, N01-HB-97053), Medical College of Georgia (N01-HB-73000, N01-HB-97060), Washington University (N01-HB-73001, N01-HB-97071), Jewish Hospital and Medical Center of Brooklyn (N01-HB-73002), Trustees of Health and Hospitals of the City of Boston, Inc., (N01-HB-73003), Children's Hospital-Oakland (N01-HB-73004, N01-HB-97054), University of Mississippi (N01-HB-73005), St. Luke's Hospital-New York (N01-HB-73006), Alta Bates-Herrick Hospital (N01-HB-97051), Columbia University (N01-HB-97058), St. Jude's

Children's Research Hospital (N01-HB-97066), Research Foundation, State University of New York-Albany (N01-HB-97068, N01-HB-97069), New England Research Institute (N01-HB-97073), Interfaith Medical Center-Brooklyn (N01-HB-97085); **Coronary Artery Risk in Young Adults (CARDIA)**: University of Alabama at Birmingham (N01-HC-48047), University of Minnesota (N01-HC-48048), Northwestern University (N01-HC-48049), Kaiser Foundation Research Institute (N01-HC-48050), University of Alabama at Birmingham (N01-HC-95095), Tufts-New England Medical Center (N01-HC-45204), Wake Forest University (N01-HC-45205), Harbor-UCLA Research and Education Institute (N01-HC-05187), University of California, Irvine (N01-HC-45134, N01-HC-95100); **Framingham Heart Study (FHS)**: Boston University (N01-HC-25195); **Jackson Heart Study (JHS)**: Jackson State University (N01-HC-95170), University of Mississippi (N01-HC-95171), Tougaloo College (N01-HC-95172); **Multi-Ethnic Study of Atherosclerosis (MESA)**: University of Washington (N01-HC-95159), Regents of the University of California (N01-HC-95160), Columbia University (N01-HC-95161), Johns Hopkins University (N01-HC-95162), University of Minnesota (N01-HC-95163), Northwestern University (N01-HC-95164), Wake Forest University (N01-HC-95165), University of Vermont (N01-HC-95166), New England Medical Center (N01-HC-95167), Johns Hopkins University (N01-HC-95168), Harbor-UCLA Research and Education Institute (N01-HC-95169); **Sleep Heart Health Study (SHHS)**: Johns Hopkins University (U01 HL064360), Case Western University (U01 HL063463), University of California, Davis (U01 HL053916), University of Arizona (U01 HL053938), University of Minnesota (relocating in 2006 to University Arizona) (U01 HL053934), University of Pittsburgh (U01 HL077813), Boston University (U01 HL053941), MedStar Research Institute (U01 HL063429), Johns Hopkins University (U01 HL053937).

Replication Cohorts

EchoGEN: The support for the Echo Genetics cohort is listed by study:

Cardiovascular Health Study: Contract numbers N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01-HC-15103, N01-HC-55222, N01-HC-75150, N01-HC-45133, grant numbers U01 HL080295 and R01 HL087652 from the National Heart, Lung, and Blood Institute. DNA handling and genotyping was supported in part by National Center for Research Resources grant M01RR00069 to the Cedars-Sinai General Clinical Research Center Genotyping core and National Institute of Diabetes and Digestive and Kidney Diseases grant DK063491 to the Southern California Diabetes Endocrinology Research Center.

Rotterdam Study: The genome-wide association's database of the Rotterdam Study was funded through the Netherlands Organization of Scientific Research NWO (nr. 175.010.2005.011, 911.03.012) and the Research Institute for Diseases in the Elderly (RIDE).

This study was supported by the Netherlands Genomics Initiative (NGI)/NWO project number 050 60 810. The Rotterdam Study is supported by the Erasmus Medical Center and Erasmus University, Rotterdam; the Netherlands organization for scientific research (NWO), the Netherlands Organization for Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Netherlands Heart Foundation, the Ministry of Education, Culture and Science, the Ministry of Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. We thank Michael Moorhouse, PhD, Department of Bioinformatics, and Pascal Arp, BSc, Mila Jhamai, BSc, Marijn Verkerk, BSc, and Sander Bervoets, BSc, Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands, for their help in creating the database.

MONICA-KORA: The study was funded by the European Union sponsored project Cardiogenics (LSHM-CT 2006-037593), by the National Genome Network (01GS0418 to Drs Schunkert and Erdmann; 01GR0466 to Dr Ziegler) and by the National Genome Network Plus sponsored by the German Federal Ministry of Education and Research (BMBF). The MONICA/KORA Augsburg studies were financed by the Helmholtz Zentrum München (former GSF)–National Research Center for Environmental Health, Neuherberg, Germany, and supported by grants from the BMBF and Munich Center of Health Sciences (MC Health) as part of LMUinnovativ.

Framingham Heart Study: This work was supported by the National Heart, Lung, and Blood Institute's Framingham Heart Study (Contract No. N01-HC- 25195) and its contract with Affymetrix, Inc for genotyping services (Contract No. N02-HL-6-4278), and by grants from the National Heart, Lung, and Blood Institute 2K24HL04334, RO1HL080124, RO1HL077477, and RO1HL093328 (all to Dr. Vasan).

Gutenberg Heart Study: The Gutenberg Heart Study is funded through the government of Rheinland-Pfalz ("Stiftung Rheinland Pfalz für Innovation," contract number AZ 961-386261/733), the research programs "Wissen schafft Zukunft" and "Schwerpunkt Vaskuläre Prävention" of the Johannes Gutenberg-University of Mainz and its contract with Boehringer Ingelheim and PHILIPS Medical Systems including an unrestricted grant for the Gutenberg Heart Study. Specifically, the research reported in this article was supported by the National Genome Network "NGFNplus" (contract number project A3 01GS0833) by the Federal Ministry of Education and Research, Germany.

Study of Health in Pomerania (SHIP): SHIP is funded by the Federal Ministry of Education and Research (grants No. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social Ministry of the

Federal State of Mecklenburg-West Pomerania. Echocardiography in the 5-year follow-up was funded by the Competence Network Heart Failure of the Federal Ministry of Education and Research, and statistical analyses were supported by Deutsche Forschungsgemeinschaft (by grant SFB TR 19). Genome-wide data have been supported by the Federal Ministry of Education and Research (grant No.03ZIK012) and a joint grant from Siemens Healthcare, Erlangen, Germany, and by the Federal State of Mecklenburg- West Pomerania.

Austrian Stroke Prevention Study: Current analyses of the Austrian Stroke Prevention Study are funded by the Austrian Science Fund Project P20545_P05 Genetics of cerebral small vessel disease (Dr H. Schmidt).

Mayo Clinic, Olmsted County: Dr Rodheffer was supported in part by RO1 HL55502.

GENOA: Genetic Epidemiology Network of Arteriopathy (GENOA) study is supported by the National Institutes of Health, grant numbers HL087660 and HL100245 from National Heart, Lung, Blood Institute, and MD002249 from National Institute on Minority Health and Health Disparities." Kristin Meyers received additional funding through the National Center for Advancing Translation Sciences (NCATS) grant 9U54TR000021.



HyperGEN : The HyperGEN network is funded by cooperative agreements (U10) with the National Heart, Lung, and Blood Institute: HL54471, HL54472, HL54473, HL54495, HL54496, HL54497, HL54509, HL54515, and 2 RO1 HL55673-12.

Role of the Sponsor: The funding sources had no role in the study design, analyses, or drafting of the manuscript. The NHLBI reviews all manuscripts submitted for publication but it was not involved in the decision to publish.

References

1. Arnett DK, Devereux RB, Kitzman D, Oberman A, Hopkins P, Atwood L, et al. Linkage of left ventricular contractility to chromosome 11 in humans: The HyperGEN Study. *Hypertension*. 2001; 38:767–772. [PubMed: 11641284]
2. Tsujita Y, Iwai N, Tamaki S, Nakamura Y, Nishimura M, Kinoshita M. Genetic mapping of quantitative trait loci influencing left ventricular mass in rats. *Am J Physiol Heart Circ Physiol*. 2000; 279:H2062–H2067. [PubMed: 11045938]
3. Di Nicolantonio R, Kostka V, Kwitek A, Jacob H, Thomas WG, Harrap SB. Fine mapping of Lvm1: a quantitative trait locus controlling heart size independently of blood pressure. *Pulm Pharmacol Ther*. 2006; 19:70–73. [PubMed: 16286240]
4. Innes BA, McLaughlin MG, Kapuscinski MK, Jacob HJ, Harrap SB. Independent genetic susceptibility to cardiac hypertrophy in inherited hypertension. *Hypertension*. 1998; 31:741–746. [PubMed: 9495256]
5. Post WS, Larson MG, Myers RH, Galderisi M, Levy D. Heritability of left ventricular mass: the Framingham Heart Study. *Hypertension*. 1997; 30:1025–1028. [PubMed: 9369250]
6. Swan L, Birnie DH, Padmanabhan S, Inglis G, Connell JM, Hillis WS. The genetic determination of left ventricular mass in healthy adults. *Eur Heart J*. 2003; 24:577–582. [PubMed: 12643891]
7. Tang W, Arnett DK, Devereux RB, Province MA, Atwood LD, Oberman A, et al. Sibling resemblance for left ventricular structure, contractility, and diastolic filling. *Hypertension*. 2002; 40:233–238. [PubMed: 12215459]
8. Arnett DK, Hong Y, Bella JN, Oberman A, Kitzman DW, Hopkins PN, et al. Sibling correlation of left ventricular mass and geometry in hypertensive African Americans and whites: the HyperGEN study. *Hypertension Genetic Epidemiology Network*. *Am J Hypertens*. 2001; 14:1226–1230. [PubMed: 11775131]
9. Arnett DK. Genetic contributions to left ventricular hypertrophy. *Curr Hypertens Rep*. 2000; 2:50–55. [PubMed: 10981127]
10. Meyers KJ, Mosley TH, Fox E, Boerwinkle E, Arnett DK, Devereux RB, et al. Genetic variations associated with echocardiographic left ventricular traits in hypertensive blacks. *Hypertension*. 2007; 49:992–999. [PubMed: 17339538]
11. Vasan RS, Larson MG, Aragam J, Wang TJ, Mitchell GF, Kathiresan S, et al. Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study. *BMC Med Genet*. 2007; 8 (Suppl 1):S2. [PubMed: 17903301]

12. Vasan RS, Glazer NL, Felix JF, Lieb W, Wild PS, Felix SB, et al. Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. *JAMA*. 2009; 302:168–178. [PubMed: 19584346]
13. Pearson TA, Manolio TA. How to interpret a genome-wide association study. *JAMA*. 2008; 299:1335–1344. [PubMed: 18349094]
14. Musunuru K, Lettre G, Young T, Farlow DN, Pirruccello JP, Ejebe KG, et al. Candidate Gene Association Resource (CARE): Design, Methods, and Proof of Concept. *Circ Cardiovasc Genet*. 2010; 3:267–275. [PubMed: 20400780]
15. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. *Am J Cardiol*. 1986; 57:450–458. [PubMed: 2936235]
16. Korn JM, Kuruvilla FG, McCarroll SA, Wysoker A, Nemesh J, Cawley S, et al. Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs. *Nat Genet*. 2008; 40:1253–1260. [PubMed: 18776909]
17. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet*. 2007; 81:559–575. [PubMed: 17701901]
18. Parra EJ, Marcini A, Akey J, Martinson J, Batzer MA, Cooper R, et al. Estimating African American admixture proportions by use of population-specific alleles. *Am J Hum Genet*. 1998; 63:1839–1851. [PubMed: 9837836]
19. Zhu X, Luke A, Cooper RS, Quertermous T, Hanis C, Mosley T, et al. Admixture mapping for hypertension loci with genome-scan markers. *Nat Genet*. 2005; 37:177–181. [PubMed: 15665825]
20. Hao K, Chudin E, McElwee J, Schadt EE. Accuracy of genome-wide imputation of untyped markers and impacts on statistical power for association studies. *BMC Genet*. 2009; 10:27. [PubMed: 19531258]
21. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature*. 2007; 447:661–678. [PubMed: 17554300]
22. Veyrieras JB, Kudaravalli S, Kim SY, Dermitzakis ET, Gilad Y, Stephens M, et al. High-resolution mapping of expression-QTLs yields insight into human gene regulation. *PLoS Genet*. 2008; 4:e1000214. [PubMed: 18846210]
23. Freimer NB, Sabatti C. Human genetics: variants in common diseases. *Nature*. 2007; 445:828–830. [PubMed: 17293879]
24. Bodmer W, Bonilla C. Common and rare variants in multifactorial susceptibility to common diseases. *Nat Genet*. 2008; 40:695–701. [PubMed: 18509313]
25. Askland K, Read C, Moore J. Pathways-based analyses of whole-genome association study data in bipolar disorder reveal genes mediating ion channel activity and synaptic neurotransmission. *Hum Genet*. 2009; 125:63–79. [PubMed: 19052778]
26. Thomas NA, Koudijs M, van Eeden FJ, Joyner AL, Yelon D. Hedgehog signaling plays a cell-autonomous role in maximizing cardiac developmental potential. *Development*. 2008; 135:3789–3799. [PubMed: 18842815]
27. Saucerman JJ, McCulloch AD. Cardiac beta-adrenergic signaling: from subcellular microdomains to heart failure. *Ann N Y Acad Sci*. 2006; 1080:348–361. [PubMed: 17132794]
28. Pennica D, King KL, Shaw KJ, Luis E, Rullamas J, Luoh SM, et al. Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. *Proc Natl Acad Sci U S A*. 1995; 92:1142–1146. [PubMed: 7862649]









Figure 1. Manhattan plots showing the genome-wide $-\log_{10} p$ values for interrogated single nucleotide polymorphisms across the 22 autosomal chromosomes for (A) left ventricular

mass, (B) left ventricular internal diastolic diameter, (C) interventricular septal wall thickness, (D) and left ventricular ejection fraction. Chr; Chromosome











Figure 2. Forest plots for (A) left ventricular mass, (B) left ventricular internal diastolic diameter, (C) interventricular septal wall thickness, and (D) left ventricular ejection fraction are shown. For each cardiac trait the odds ratios are shown for cohort specific analyses and for the meta-analysis. ARIC, Atherosclerosis Risks in Communities Study; CARDIA, Coronary Artery Risk Development in Young Adults; JHS, Jackson Heart Study; MESA, Multi-Ethnic Study of Atherosclerosis; Chr; Chromosome








Figure 3.

“Results ($-\log_{10} P$) are shown for SNPs in the region flanking 250kb on either side of the marker SNPs. The marker SNPs and r^2 values of other SNPs are shown in red color. The genes within the region of interest are annotated and are shown in green arrow We investigated the association between genome-wide markers with cardiac structure and systolic function using data from four community-based cohorts of African Americans in the Candidate-gene Association Resource study. Findings from this analysis may help us better understand the role genes play in development and progression of cardiac end organ damage in African Americans. This is particularly important given the current racial disparity in LV hypertrophy and dysfunction (both of which are predictors of cardiovascular morbidity and mortality). Findings in this study warrant further investigation including replication analysis in much larger samples, and identification of potential biological mechanisms explaining the association of these variants to phenotypic findings on cardiac imaging.

Table 1

Study Sample Characteristics

	Atherosclerosis Risk in Communities		Coronary Artery Risk Development in Young Adults Study		Jackson Heart Study		Multi-Ethnic Study of Atherosclerosis	
	Women	Men	Women	Men	Women	Men	Women	Men
Age (mean±SD), y	59±6	59±6	30±4	29±4	55±13	54±13	62±10	62±10
Height, cm	163±6	176±7	164±7	177±7	164±7	177±7	162±7	176±7
Weight, lbs	186±41	190±36	167±47	183±40	196±47	209±48	182±39	196±36
Echocardiographic Traits								
N	698	415	854	589	1884	1115	647	563
LV Mass, g	242±78	289±96	136±40	177±44	140±34	167±42	137±30	184±39
LV diastolic dimension, cm	4.6±0.6	4.9±0.6	4.8±0.45	5.1±0.47	4.87±0.41	5.1±0.4		
Left atrial dimension, cm	3.9±0.6	3.9±0.6	3.5±0.5	3.6±0.48				
Aortic root diameter, cm	3.0±0.4	3.4±0.4	2.6±0.3	3.0±0.35	3.0±0.28	3.4±0.3		
Posterior wall thickness, cm	1.1±0.2	1.2±0.2	0.8±0.1	0.9±.14	0.8±0.1	0.9±0.1		
Fractional shortening, % < 0.29	19.6	9.2	6.4	7.6	3.8	8.0		
Ejection Fraction, % < 0.50	5.3	2.5	*0.7	*1.2	1.6	4.2	1.1	5.0
LV systolic dimension, cm					2.9±0.4	3.2±0.5		
Interventricular septal wall thickness, cm	1.2±0.2	1.2±0.3	0.9±0.2	1.0±0.16	0.9±0.1	0.9±0.15		

MRI, magnetic resonance imaging; g, grams; cm, centimeters;

* For the CARDIA study there were 13 participants with ejection fraction, which was too small to warrant meaningful analysis, at least 22 cases was the minimum for dichotomous trait analyses.

Table 2

Genome-Wide significant SNPs associated with cardiac traits ($P < 4.0 \times 10^{-7}$) and results from replication analyses

Trait	Meta-Analysis of 3 CARe Cohorts										Replication Studies					
	Locus	SNP	SNP position (bp)	Minor/Major	SNP type	Nearest gene	MAF	Effect size β (SE)	Meta-analysis P	GENOA (n=651) Beta	P	HyperGEN (n=1316) Beta	P	CHS (n=501) Beta	P	
LV Mass	8q11	rs4552930	49170958	G/A [†]	Intergenic	<i>UBE2V2</i>	0.05	0.059 (0.010)	1.42×10^{-7}	0.042 (.029)	0.14	-5.49 (3.35)	0.10	0.034 (.036)	0.34	
LV internal diastolic diameter	17q24	rs7213314	64197442	T/C [†]	Intergenic	<i>WPI1; PRKAR1A; FAM20A; ABCA8</i>	0.17	0.017 (0.003)	1.68×10^{-7}	0.009 (.011)	0.40	-0.03 (.012)	0.14	-0.008 (.01)	0.41	
Intraventricular septal wall thickness	10q26	rs1571099	122256604	C [†] /T	intronic	<i>PPAPDC1A</i>	0.11	-0.036 (0.007)	2.57×10^{-8}					-0.003 (.019)	0.88	
Ejection fraction	13q22	rs9530176	72716729	A [†] /T	Intergenic	<i>KLF5; PIBF1</i>	0.07	1.240 (0.240)	4.02×10^{-7}			-0.34 (0.56)	0.55			

SNP, single nucleotide polymorphism; bp, base pairs; MAF, minor allele frequency; LV, left ventricular;

[†] Coded allele